Hin Sang Group International Holding Co Ltd (6893) Fair Value & Analysis

Consumer Defensive · HK · Market cap HK$198M

Below-average quality, and screening another 61% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (HK$0.1300). The favourable scenario is already priced in.
• Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (HK$0.0600 to HK$0.1300) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.0980 – HK$0.5400 · fair‑value band HK$0.0600 – HK$0.1300 · the HK$0.2290 price screens above the HK$0.0900 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Hin Sang Group International Holding Co Ltd (6893) currently trades at HK$0.2290, while our model-based Fair Value estimate is HK$0.0900, implying the stock looks roughly 60.7% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Hin Sang Group International Holding Co Ltd generated revenue of HK$95.5M at a net margin of -42.0%. Revenue grew 7.9% year over year. It earns a return on equity of -23.4%. Net debt stands at HK$331M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.0600 (bear case) to HK$0.1300 (bull case); at HK$0.2290, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high and 146% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -38% fair-value upside, at -61%, 6893 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Hin Sang Group (International) Holding Co. Ltd., together with its subsidiaries, engages in the manufacture, marketing, and sale of healthcare products for children in Hong Kong and Mainland China. It operates in four segments: Product Development, Brand Development and Management, Trading of Goods, and Healthcare.

Full company description

Hin Sang Group (International) Holding Co. Ltd., together with its subsidiaries, engages in the manufacture, marketing, and sale of healthcare products for children in Hong Kong and Mainland China. It operates in four segments: Product Development, Brand Development and Management, Trading of Goods, and Healthcare. The Product Development segment develops and sells personal care products, household products, and health supplements under the Hin Sang, Tai Wo Tong, Yabune, Weverse, Care Plus, and King's Antiseptic brands. Its Brand Development and Management segment engages in marketing, selling and distribution, logistics, and delivery services of personal care products; and manages and develops brands for its brand proprietors. The Trading of Goods segment engages in the trading, distribution, and sale of skin care products, personal care products, and household products purchased from various authorized dealers, independent traders, manufacturers, parallel importers, and suppliers. Its Healthcare segment engages in the provision of Chinese medical healthcare, including medical treatment and consultation by Chinese physicians for mothers and children; and the development of mother and child-related health products, medical centers, and related services. The company is also involved in property and investment holding activities. It serves retailers and distributors, and directly to customers through its retail outlets and online channel. The company was founded in 1996 and is headquartered in Tsim Sha Tsui, Hong Kong. Hin Sang Group (International) Holding Co. Ltd. is a subsidiary of Genwealth Group Holding Company Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Hin Sang Group International Holding Co Ltd reported revenue of HK$91.9M in FY2025 versus HK$119M in FY2021, a compound −6.3%/yr. Reported net income was −HK$49.4M in FY2025.

6893 screens 61% overvalued. Compare with The Procter & Gamble Company →

Peer Group

Household & Personal Products · 252 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Household & Personal Products median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.